Business Wire

Alorica and Talkdesk Announce Strategic Partnership to Deploy Next Generation of Customer Experience

Share

Alorica, a global leader in customer experience (CX) solutions, and Talkdesk®, Inc., the leading cloud contact center for innovative enterprises, today announced a strategic partnership to deliver turnkey CX solutions. The partnership brings together Talkdesk’s cloud-based contact center platform with Alorica’s award-winning operational execution and best-in-class workforce, providing clients with a complete solution to build customer satisfaction, loyalty and long-term value through a scalable, cost-efficient and secure implementation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005568/en/

“Many businesses are facing the challenge of needing to invest and scale more robust customer service and experience requirements amidst uncertain economic outlooks,” said Greg Haller, chief operating officer, Alorica. “With a deep understanding of the customer and how digital platforms are redefining our industry, Alorica is investing in the right technology and partners that will help our clients navigate their CX transformation successfully. The combined, complementary capabilities of Alorica and Talkdesk give clients a differentiated pathway to cost-effectively elevate the customer experience. Ultimately, this leads to brand loyalty, revenue growth and operational efficiencies.”

Modern consumer expectations have advanced beyond voice-only support to include web, messaging, mobile applications and social platforms as part of the customer journey. In response, service models must deliver fast and easy customer engagement, across all channels, in a way that is both personalized and contextual at every customer touchpoint. However, companies are challenged to activate new technology, high-quality talent and world-class operational models at an accelerated pace while simultaneously reducing risk and improving efficiency.

“Talkdesk is passionate about driving the contact center industry forward with innovative solutions, providing companies with the solutions and flexible consumption-based pricing options they need to set themselves apart from their competition,” said Tiago Paiva, chief executive officer, Talkdesk. “The customer-first philosophy shared by Alorica and Talkdesk helps enterprises around the world build brand trust and loyalty by delivering exceptional customer interactions.”

Alorica and Talkdesk are joining forces to achieve these goals, enabling a more comprehensive understanding of client needs and the ability to quickly provide tailored offerings. Through their combined capabilities, clients will benefit from an integrated operating model for hiring, training, analytics, knowledge management, quality assurance, call routing and automation. Talkdesk’s native cloud platform complements Alorica’s embedded systems and empowers a skilled workforce, giving clients an industry-leading and strategic executional partner to efficiently establish and scale the latest CX solutions through a single interface at a fraction of the cost of building standalone operations.

By leveraging Talkdesk CX Cloud™, Alorica further enhances its enterprise performance at scale on behalf of clients around the world, resulting in increased productivity, customer satisfaction and cost savings. Through this one-of-a-kind partnership, Alorica and Talkdesk are setting a new benchmark for the contact center solutions market with scalability, security and reliability. This is backed not only by Talkdesk’s 100% uptime Service Level Agreement, but also implemented through one of the largest customer experience providers in the world—Alorica.

Additional Resources:

Tweet this : Ready for the next generation of #CX? @OfficialAlorica and @Talkdesk are excited to announce a new strategic partnership as an integrated solution to help brands deploy global omnichannel experiences tailored to their business

Social Networks:

About Alorica

We are made up of 100,000 passionate problem solvers who make lives better through positive customer interactions—at every touchpoint—across voice, chat and social. Leveraging innovative technologies—including intelligent automation and a comprehensive analytics suite—we support the world’s most respected brands with the best talent and resources necessary to create insanely great experiences. Alorica provides a host of world-class services—from customer care to financial solutions and digital services—to clients across industries of all kinds, many of whom are on the Fortune 500. Alorica contact centers and operation hubs span the globe with locations in 14 countries. To learn more, visit www.Alorica.com.

About Talkdesk

Talkdesk® is the cloud contact center for innovative enterprises. Combining enterprise performance with consumer simplicity, Talkdesk easily adapts to the evolving needs of support and sales teams and their end-customers, resulting in higher customer satisfaction, productivity and cost savings. Over 1,800 innovative companies around the world, including IBM, Acxiom, 2U, Trivago and YMCA rely on Talkdesk to make customer experience their competitive advantage. Learn more and request a demo at www.talkdesk.com.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alorica
Sunny Yu
sunny.yu@alorica.com
(714) 469-8385

Talkdesk
Christie Blake
christie.blake@talkdesk.com
(781) 405-3616

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 15:30:00 EEST | Press release

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release

Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as

New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release

Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye